China-based genomic research organisation, BGI Genomics, announced on Wednesday the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya, a Slovak-based company involved in providing patients with the latest technology in genetic screening.
COLOTECTTM 1.0 is one of the first-ever faecal DNA tests for colorectal cancer that is available in Slovakia. It is a non-invasive faecal DNA test for detecting colorectal cancer and precancerous lesions. It uses multiplex methylation-specific PCR technology to trace abnormal colorectal cancer DNA-methylation biomarkers from fecal samples.
A product launch press conference was held in Bratislava, Slovakia. Dr Martin Huroka (chief gastroenterology specialist, Ministry of Health), Dr Lucia Starovecka Copak (medical geneticist), and Dr Jozef Dolinsky (clinical oncologist), were the invited speakers.
Early detection is the key to the prevention of colorectal cancer and the improvement of survival rate because the progression of colorectal cancer development is generally very slow. It can take 10 to 15 years to develop from normal epithelium to adenomatous polyps and then undergo malignant transformation to become colorectal cancer.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886